论文部分内容阅读
目的:探讨利妥昔单抗注射液(美罗华)联合CHOP方案(R-CHOP)与标准CHOP方案治疗非霍奇金淋巴瘤(NHL)的疗效观察及护理方法。方法:106例患者随机分为标准CHOP方案组54例与R-CHOP方案组52例,观察两组不良反应的发生情况。两组化疗前均给予异丙嗪针肌内注射、地塞米松针静脉注射和5-HT3拮抗剂预防毒副反应的发生。结果:R-CHOP组的畏寒、寒战、发热、胸闷、气促、面色和口唇苍白等副反应明显高于标准CHOP方案组。结论:R-CHOP组的副反应的发生率明显高于标准CHOP组,在临床工作中要加以重视。
Objective: To investigate the efficacy and nursing of Rituximab injection (Rituximab) combined with CHOP regimen (R-CHOP) and standard CHOP regimen in the treatment of non-Hodgkin’s lymphoma (NHL). Methods: A total of 106 patients were randomly divided into standard CHOP group (n = 54) and R-CHOP group (n = 52). The incidence of adverse reactions in both groups was observed. Both groups were given promethazine intramuscular injection before chemotherapy, dexamethasone needle injection and 5-HT3 antagonist to prevent the occurrence of side effects. Results: The side effects of chills, chills, fever, chest tightness, shortness of breath, pale complexion and pale lips in R-CHOP group were significantly higher than those in standard CHOP group. Conclusion: The incidence of side effects in the R-CHOP group was significantly higher than that of the standard CHOP group, and attention should be paid in clinical work.